Patent ID: 9518126
Filing Date: 2016-12-13
CPC Classification: A61K,A61P,C07K,C12N,Y02A

Claim Text:
1. An immunotherapeutic vaccine comprising immature myeloid cells (IMCs) loaded with a natural killer T cell ligand and a target antigen, the IMCs comprising natural killer T cell ligand loaded on CD1d and a target antigen loaded on major histocompatibility complex (MHC) molecules, wherein the IMCs are obtained from a tumor-bearing subject; wherein the IMCs express GR-1 and CD11b simultaneously on their surface; wherein the natural killer T cell ligand is α-galactosylceramide; wherein the target antigen is a fragment of a full-length protein derived from a tumor or a pathogen; and wherein the vaccine activates cytotoxic T cells specific for said target antigen.